Posted by Michael Wonder on 16 Nov 2015
Nivolumab in non small-cell lung cancer: evidence of a considerable additional benefit in patients under 75 years of age according to IQWiG
16 November 2015 - For patients under 75 year of age with a relatively good general condition, there is an indication of a significant additional benefit.
For more details, go to: https://www.iqwig.de/de/presse/pressemitteilungen/pressemitteilungen/nivolumab-bei-nicht-kleinzelligem-lungenkarzinom-hinweis-auf-erheblichen-zusatznutzen-fur-unter-75-jahrige.7060.html?&et_cid=4&et_lid=%25208
